Revolving Door Of Executive Changes At Perrigo As Firm Revises Its Expectations Up
Firm Has Experienced Notable Disruption Due To Ukraine Conflict
Perrigo is set to welcome a new chief financial officer and corporate security head as it rounds up a fairly successful first quarter.
You may also be interested in...
“We said we would start growing this company ... and this is the year to do it,” says CERO Murray Kessler. With nearly 11% net sales growth for its Americas business leading nearly 10% overall Q1 growth, Perrigo raises full-year guidance for net sales growth to 8% to 9%, up earlier 7% to 8%.
Perrigo has announced a deal to acquire consumer healthcare company HRA Pharma for €1.8bn. The move comes after the firm shed the majority of its prescription pharmaceuticals interests in recent years and completes its transformation into a fully self-care focused company.
Canadian provinces must consider the impact of inflation on generic drugs during the next round of off-patent price setting, says a study from Aviseo and the Canadian Generic Pharmaceutical Association.